Quantitative monitoring of circulating Tumor DNA predicts response of Cutaneous Metastatic Melanoma to Anti-PD1 Immunotherapy

ABSTRACT

Introduction: Anti-PD1 immunotherapies are drastically changing the current standard of care of metastatic cutaneous melanoma. However, about 60 percent of the treated patients do not respond to anti-PD1, and atypical radiological responses delays the detection of primary resistances. The objective of this study was to determine whether the quantitative monitoring of circulating tumor DNA [ctDNA] could early predict the tumor response to anti-PD1